In seven CRC PDXs with varying levels of basal EGFR, AKT, and ERK1/2 activation before GC1118 treatment (Figure 4A), including an additional CRC-024T model (KRAS G12D; high-affinity ligand, 88.8%; low-affinity ligand, 11.2%; high basal AKT activity) with resistance to GC1118 and cetuximab (TGII-GC1118 = 65.6) (Table S2), the efficacy of GC1118 (TGII) showed a significant positive correlation with basal AKT activity only (Pearson’s r = 0.82, p = 0.024) (Figure 4B). Here, KRAS is linked to colorectal carcinoma.